HUTCHMED (China) Limited (HCM) Stock Price & Analysis
HUTCHMED (China) Limited (HCM) closed at USD 14.28 on Thursday, October 22, 2026, down 0.63% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 14.37; the Oct 22, 2026 session ranged USD 14.22–14.36 on volume of 23,358 shares. Market capitalization is $2.48B, with a 52-week range of USD 9.77–16.33 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:06 UTC.
Also available as compact Markdown for AI agents: nexqual.com/HCM.md
Key facts (HCM)
- Analysts: Buy (mean 2.08 on a 1–5 scale) (12 analysts), mean target USD 20.59 (range 13.6–33.27).
- Total return with dividends: 1Y -5.0% vs S&P 500 +14.9%; 5Y -55.6% vs S&P 500 +80.3%.
- Next earnings: 2026-07-30, EPS estimate USD —, revenue estimate $0K.
Analysts (HCM)
Consensus Buy (mean 2.08 on a 1–5 scale), 12 analysts; mean target USD 20.59 (low 13.6, high 33.27).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-23 | Goldman Sachs | Target lowered | Neutral | $16 → $14 |
| 2026-07-07 | B of A Securities | Target lowered | Buy | $20 → $17 |
Total return (dividends reinvested) (HCM)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -5.0% | -55.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -5.1% | -15.0% |
| Volatility (annualized) | 38.1% | 59.5% |
| Max drawdown | -37.8% (Jan 2026→Jun 2026) | -77.4% (Dec 2021→Oct 2022) |
HCM suppliers, customers and competitors (named in its 20-F)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Shanghai Hutchison Pharmaceuticals | “Revenue from our Other Ventures also comprises revenue from sales of Zhi Ling Tong infant nutrition and other health supplement products manufactured by Hutchison Healthcare and distributed through Shanghai Hutchison Pharmaceuticals, organic and natural products by Hutchison Hain Organic (which was divested in December 2023), and certain third-party consumer products distributed and marketed by HUTCHMED Science Nu…” |
| Partner | Eli Lilly (LLY) | “We and our collaboration partners, including AstraZeneca, Eli Lilly, Takeda, ImageneBio, Miragene, Innovent, and Epizyme, Inc. (a subsidiary of Ipsen Pharma SAS, "Epizyme") may experience delays in completing our pre-clinical or clinical trials, and numerous unforeseen events could arise during, or as a result of, future clinical trials, which could delay or prevent us from receiving regulatory approval, including:” |
| Partner | Group and Takeda Pharmaceuticals International | “Our collaborations, including those with our oncology drug partners AstraZeneca, Eli Lilly and Takeda and our in-licensing arrangement with Epizyme, and any future collaborations that we enter into may not be successful.” |
| Partner | Epizyme | “Our collaborations, including those with our oncology drug partners AstraZeneca, Eli Lilly and Takeda and our in-licensing arrangement with Epizyme, and any future collaborations that we enter into may not be successful.” |
| Partner | Hutchison Whampoa Enterprises | “The Brand License Agreement contains provisions on quality control pursuant to which we are obliged to use the brands and related materials in compliance with the brand guidelines, industry best practice and other quality directives issued by Hutchison Whampoa Enterprises Limited from time to time.” |
| Partner | ImageneBio, Inc. (IMA) | “We and our collaboration partners, including AstraZeneca, Eli Lilly, Takeda, ImageneBio, Miragene, Innovent, and Epizyme, Inc. (a subsidiary of Ipsen Pharma SAS, "Epizyme") may experience delays in completing our pre-clinical or clinical trials, and numerous unforeseen events could arise during, or as a result of, future clinical trials, which could delay or prevent us from receiving regulatory approval, including:” |
| Partner | Jiangsu Hengrui Pharmaceuticals | “In 2024, we entered into a collaboration with Jiangsu Hengrui Pharmaceuticals Co., Ltd ("Hengrui") to evaluate the combination of Sulanda, the Hengrui PD-1 antibody camrelizumab, nab-paclitaxel and gemcitabine as a first-line treatment for patients with metastatic PDAC in China.” |
| Partner | Luye Pharma Hong Kong | “The terms of our agreement with AstraZeneca were assigned to Luye Pharma Hong Kong Ltd., or Luye Pharma HK.” |
| Partner | Hutchison Whampoa | “The Services Agreement replaces our prior services agreement with Hutchison Whampoa (China) Limited, dated April 21, 2006, which had substantially similar terms.” |
Quoted from the company's 20-F filed Mar 5, 2026.
HCM analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends Dec 2026) | $0.22 | $0.36 | -37.5% | $626.6M | 6 |
| Next fiscal year (ends Dec 2027) | $0.26 | $0.49 | -47.5% | $698.8M | 6 |
HCM options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 132.8% | ±9.8% |
| Feb 19, 2027 | 119 | 75.2% | ±37.1% |
30-day implied volatility 78.7% vs 43.6% realized over the last 30 trading days. Put/call ratio (volume) 0.07. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 10:06 UTC)
| Price | USD 14.28 |
|---|---|
| Change | ▼ 0.63% (down) |
| Previous Close | USD 14.37 |
| Open | USD 14.26 |
| Day Range | USD 14.22 – 14.36 |
| 52-Week Range | USD 9.77 – 16.33 |
| Volume | 23,358 shares |
| Market Cap | $2.48B |
| Exchange | NMS |
Technical Analysis (HCM)
Nexqual's technical model rates HCM "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 10:06 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 51.97 (neutral) |
| vs SMA50 | Above (USD 13.49) |
| MACD | 0.2 (positive) |
Analyst Ratings (HCM)
Wall Street analysts rate HCM "Buy" based on 12 analysts, with a mean price target of USD 20.59 (range USD 13.6–33.27), per Nexqual as of October 23, 2026 at 10:06 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 20.59 |
| High Target | USD 33.27 |
| Low Target | USD 13.6 |
| Buy / Hold / Sell | 10 / 2 / 0 |
Earnings (HCM)
| Next Earnings Date | 2026-07-30 |
|---|
Source: Nexqual, October 23, 2026 at 10:06 UTC.
Financials & Fundamentals (HCM)
| Total Revenue | $549.12M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +0.20% |
| Gross Margin | +13.31% |
| Operating Margin | +0.31% |
| Profit Margin | +3.26% |
| ROE | +1.46% |
| Debt / Equity | 0.07 |
| Current Ratio | 5.64 |
| Total Cash | $1.38B |
| Total Debt | $94.51M |
Source: Nexqual, October 23, 2026 at 10:06 UTC.
Financial Health Score (HCM)
Nexqual rates HUTCHMED (China) Limited's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:06 UTC.
| Growth | Critical — Revenue -13% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Gross margin 13%, operating 0% (last 12 months) |
| Balance Sheet | Strong — $1.38B cash vs $95M debt, net cash position |
| Cash Flow | Solid — Operating cash flow $20M (TTM) |
| Efficiency | Weak — ROE 1%, ROA -1.2% |
Ownership (HCM)
| Insider Ownership | +0.01% |
|---|---|
| Institutional Ownership | +2.61% |
| Shares Outstanding | 173.81M |
| Float | 105.61M |
| Short % of Float | +0.26% |
Source: Nexqual, October 23, 2026 at 10:06 UTC.
Leadership (HCM)
HUTCHMED (China) Limited is led by Chig Fung Cheng BEc, CA, Acting CEO, CFO & Executive Director, per Nexqual as of October 23, 2026 at 10:06 UTC.
| Acting CEO, CFO & Executive Director | Chig Fung Cheng BEc, CA |
|---|---|
| CEO, Chief Scientific Officer & Executive Director (Leave of Absence) | Wei-Guo Su B.Sc. |
| Executive Vice President & Chief Technical Officer | Xinhui Hu |
| Senior Vice President of Corporate Management & Communications | Kin Hung Lee |
| Senior Vice President of Global Human Resources | Selina Zhang |
Major Backers & Investors (HCM)
Notable institutional backers of HUTCHMED (China) Limited include Schroder Investment Management Group, Aia Group Ltd, M&G Plc, according to Nexqual as of October 23, 2026 at 10:06 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Schroder Investment Management Group | 0.85% |
| Aia Group Ltd | 0.17% |
| M&G Plc | 0.14% |
| Jane Street Group, LLC | 0.11% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Allianz Asset Management GmbH | 0.39% |
| State Street | 0.18% |
| Amundi | 0.12% |
Source: Nexqual, October 23, 2026 at 10:06 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUPN | Supernus Pharmaceuticals, Inc. | USD 42.07 | ▲ 2.09% |
| BHC | Bausch Health Companies Inc. | USD 6.49 | ▲ 0.62% |
| LQDA | Liquidia Corporation | USD 39.69 | ▲ 2.14% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 28.57 | ▼ 1.58% |
| INDV | Indivior Pharmaceuticals, Inc. | USD 35.33 | ▲ 1.55% |
| RGC | Regencell Bioscience Holdings L | USD 9.81 | ▼ 9.17% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:06 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt